This brand name is authorized in France, Japan, Poland
The drug MYTELASE contains one active pharmaceutical ingredient (API):
|
1
Ambenonium chloride
UNII 51FOB87G3I - AMBENONIUM CHLORIDE
|
|
Ambenonium (as ambenonium dichloride) is a cholinesterase inhibitor used in the management of myasthenia gravis. Ambenonium exerts its actions against myasthenia gravis by competitive reversible inhibition of acetylcholinesterase, the enzyme responsible for the hydrolysis of acetylcholine. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| N07AA30 | Ambenonium | N Nervous system → N07 Other nervous system drugs → N07A Parasympathomimetics → N07AA Anticholinesterases |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: FR | Base de données publique des médicaments | Identifier(s): 60374821 |
| Country: JP | 医薬品医療機器総合機構 | Identifier(s): 1231001F1030 |
| Country: PL | Rejestru Produktów Leczniczych | Identifier(s): 100045181 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
